Bristol overtakes Amgen in colorectal
Meanwhile, Bristol’s other competition in this disease looks set to come from China.
Takeda draws a cautious line under Iclusig
$100m buys an option over another third-gen drug, but Scemblix casts a long shadow.
EHA 2024 – Syndax sets up another menin inhibitor battle
Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.
Bayer changes tack in targeted lung cancer
As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.
ASCO 2024 – Laura’s crossover conundrum
Tagrisso is a knockout on PFS, but only OS will show whether it should be given before patients progress.
ASCO 2024 – Krazati looks more similar than different to Lumakras
Meanwhile, Lilly gets in on the next-gen KRAS action.
